Literature DB >> 21380634

The duration of symptoms predicts the presence of malignancy in 210 resected cases of pancreatic intraductal papillary mucinous neoplasms.

Toshiyuki Moriya1, Yasushi Hashimoto, L William Traverso.   

Abstract

INTRODUCTION: Using Kaplan-Meier curves, a 2006 study illustrated a shorter time interval between development of symptoms and detection of malignant IPMN in the main pancreatic duct versus a side-branch duct location. Of 93 cases, only 62 were confirmed histologically. To support these interesting findings, we examined a larger cohort of cases where the diagnosis was confirmed histologically and asked if symptoms by themselves, as well as main duct location, were associated with malignant detection.
METHODS: Between 1989 and 2009, 210 IPMN cases meeting international criteria were resected and histologically examined. Actuarial rates of malignant detection over time were calculated from the first clinical symptom to malignant detection (resection). These rates of malignant detection over time were compared for main vs. side-branch duct location and symptomatic vs. asymptomatic cases.
RESULTS: The most common indications for resection were symptoms (88%) and main pancreatic duct location (65%). The actuarial malignant detection rates were significantly shorter for main duct location and also for symptomatic cases, regardless of duct location.
CONCLUSIONS: Presence of symptoms followed by main pancreatic duct location had a significantly shorter elapsed time to malignant detection. The visual depiction of these actuarial rates highlights the importance of the clinical history. To determine malignant risk, the primary determinants for resection were either symptoms or main duct location (but not cyst size), confirming the 2006 study with a larger cohort of histologically confirmed cases.

Entities:  

Mesh:

Year:  2011        PMID: 21380634     DOI: 10.1007/s11605-011-1437-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  7 in total

1.  Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct.

Authors:  B Terris; P Ponsot; F Paye; P Hammel; A Sauvanet; G Molas; P Bernades; J Belghiti; P Ruszniewski; J F Fléjou
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

Review 2.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

3.  Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors.

Authors:  G Zamboni; A Scarpa; G Bogina; C Iacono; C Bassi; G Talamini; F Sessa; C Capella; E Solcia; F Rickaert; G M Mariuzzi; G Klöppel
Journal:  Am J Surg Pathol       Date:  1999-04       Impact factor: 6.394

4.  WHO-classification 2000: exocrine pancreatic tumors.

Authors:  G Klöppel; J Lüttges
Journal:  Verh Dtsch Ges Pathol       Date:  2001

5.  Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy.

Authors:  Philippe Lévy; Vincent Jouannaud; Dermot O'Toole; Anne Couvelard; Marie Pierre Vullierme; Laurent Palazzo; Alain Aubert; Philippe Ponsot; Alain Sauvanet; Frédérique Maire; Olivia Hentic; Pascal Hammel; Philippe Ruszniewski
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04       Impact factor: 11.382

6.  Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology.

Authors:  C Max Schmidt; Patrick B White; Joshua A Waters; Constantin T Yiannoutsos; Oscar W Cummings; Marshall Baker; Thomas J Howard; Nicholas J Zyromski; Atilla Nakeeb; John M DeWitt; Fatih M Akisik; Stuart Sherman; Henry A Pitt; Keith D Lillemoe
Journal:  Ann Surg       Date:  2007-10       Impact factor: 12.969

Review 7.  Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms.

Authors:  Y M Shyr; C H Su; S H Tsay; W Y Lui
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

  7 in total
  5 in total

Review 1.  Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history.

Authors:  L William Traverso; Toshiyuki Moriya; Yasushi Hashimoto
Journal:  Curr Gastroenterol Rep       Date:  2012-04

2.  Incidental Cystic Lesions in the Pancreas: Resect? EUS? Follow?

Authors:  Linda S Lee
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

3.  Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.

Authors:  Andrew H Nguyen; Paul A Toste; James J Farrell; Barbara M Clerkin; Jennifer Williams; V Raman Muthusamy; Rabindra R Watson; James S Tomlinson; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2014-11-06       Impact factor: 3.452

Review 4.  Narrative review of intraductal papillary mucinous neoplasms: pathogenesis, diagnosis, and treatment of a true precancerous lesion.

Authors:  Gang Ma; Guichen Li; Zhihuan Xiao; Anjiang Gou; Yuanhong Xu; Shaowei Song; Kejian Guo; Zhe Liu
Journal:  Gland Surg       Date:  2021-07

Review 5.  Utility of the sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review.

Authors:  Brian K P Goh; Damien M Y Tan; Mac M F Ho; Tony K H Lim; Alexander Y F Chung; London L P J Ooi
Journal:  J Gastrointest Surg       Date:  2014-03-26       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.